|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-6-28
|
|
pubmed:abstractText |
We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-10073515,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-10739176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-11298075,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-11523725,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-11893129,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-11926893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-11927841,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-12496751,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-12724615,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-12931134,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-14691573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-15148533,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-15637526,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-8946475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-9110362,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17596671-9630825
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1011-8934
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
557-9
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17596671-Aged,
pubmed-meshheading:17596671-Anticoagulants,
pubmed-meshheading:17596671-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:17596671-Atrial Fibrillation,
pubmed-meshheading:17596671-Female,
pubmed-meshheading:17596671-Genotype,
pubmed-meshheading:17596671-Heterozygote,
pubmed-meshheading:17596671-Humans,
pubmed-meshheading:17596671-International Normalized Ratio,
pubmed-meshheading:17596671-Pharmacogenetics,
pubmed-meshheading:17596671-Polymorphism, Genetic,
pubmed-meshheading:17596671-Prothrombin Time,
pubmed-meshheading:17596671-Warfarin
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.
|
|
pubmed:affiliation |
Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|
